Thoracoscopic Mesh Repair of Diaphragmatic Defects in Hepatic Hydrothorax: A 10-Year Experience

Huang, Pei-Ming; Kuo, Shuenn‐Wen; Chen, Jin‐Shing; Lee, Jang-Ming

doi:10.1016/j.athoracsur.2015.11.023

Cited by 36 publications

(29 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…139 Finally, thoracoscopic repair with mersilene mesh appears to be effective in patients with well-defined diaphragmatic defects. 140 Advanced liver disease, as assessed by MELD score, and preoperative renal dysfunction appear to adversely affect three-month survival. Unfortunately, clear cut-off values cannot be retrieved from that study.…”

Section: Hepatic Hydrotoraxmentioning

confidence: 99%

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

Angeli¹,

Bernardi

Villanueva³

et al. 2018

Journal of Hepatology

1,954

1,750

View full text Add to dashboard Cite

The natural history of cirrhosis is characterised by an asymptomatic compensated phase followed by a decompensated phase, marked by the development of overt clinical signs, the most frequent of which are ascites, bleeding, encephalopathy, and jaundice. The following Clinical Practice Guidelines (CPGs) represent the first CPGs on the management of decompensated cirrhosis. In this context, the panel of experts, having emphasised the importance of initiating aetiologic treatment for any degree of hepatic disease at the earliest possible stage, extended its work to all the complications of cirrhosis, which had not been covered by the European Association for the Study of the Liver guidelines, namely: ascites, refractory ascites, hyponatremia, gastrointestinal bleeding, bacterial infections, acute kidney injury, hepatorenal syndrome, acute-on-chronic liver failure, relative adrenal failure, cirrhotic cardiomyopathy, hepatopulmonary syndrome, and porto-pulmonary hypertension. The panel of experts, produced these GPGs using evidence from PubMed and Cochrane database searches providing up to date guidance on the management of decompensated cirrhosis with the only purpose of improving clinical practice.

show abstract

Section: Hepatic Hydrotoraxmentioning

confidence: 99%

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

Angeli¹,

Bernardi

Villanueva³

et al. 2018

Journal of Hepatology

1,954

1,750

View full text Add to dashboard Cite

show abstract

“…( 68 ) One‐month and 3‐month mortalities after defect closure have been reported to be 9.5% and 25.4%, respectively, due to septic shock, acute renal injury, gastrointestinal bleeding, HE, and bowel ischemia. ( 7 ) Due to these limitations, diaphragmatic defects closure is performed only in selected patients who have failed or have contraindication to other treatment strategies (Fig. 1).…”

Section: Multidisciplinary Management Of Hhmentioning

confidence: 99%

Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence‐Based Review and Guidance

et al. 2020

View full text Add to dashboard Cite

“…Thoracoscopic mesh repair of diaphragmatic defects: Huang et al[ 45 ] published the results of thoracoscopic onlay reinforcement with Mersilene mesh to repair diaphragmatic defects in 63 patients with refractory HH (CTP class A - 12, B - 36, C - 15), which in 16 cases was combined with their suturing. The average observation period was 20.5 mo.…”

Section: Treatment Of Hhmentioning

confidence: 99%

Hepatic hydrothorax: An update and review of the literature

Garbuzenko

Arefyev

2017

WJH

View full text Add to dashboard Cite

This review considers the modern concepts of pathogenesis, diagnostic methods, and treatment principles of hepatic hydrothorax (HH). HH is the excessive (> 500 mL) accumulation of transudate in the pleural cavity in patients with decompensated liver cirrhosis but without cardiopulmonary and pleural diseases. It causes respiratory failure which aggravates the clinical course of liver cirrhosis, and the emergence of spontaneous bacterial pleural empyema may be the cause of death. The information was collected from the PubMed database, the Google Scholar retrieval system, the Cochrane reviews, and the reference lists from relevant publications for 1994-2016 using the keywords: “liver cirrhosis”, “portal hypertension”, “hepatic hydrothorax”, “pathogenesis”, “diagnostics”, and “treatment”. To limit the scope of this review, only articles dealing with uncomplicated hydrothorax in patients with liver cirrhosis were included. The analysis of the data showed that despite the progress of modern hepatology, the presence of HH is associated with poor prognosis and high mortality. Most patients suffering from it are candidates for orthotopic liver transplantation. In routine clinical practice, stratification of the risk for an adverse outcome and the subsequent determination of individual therapeutic strategies may be the keys to the successful management of the patient’s condition. The development of pathogenetic pharmacotherapy and optimization of minimally invasive treatment will improve the quality of life and increase the survival rate among patients with HH.

show abstract

Thoracoscopic Mesh Repair of Diaphragmatic Defects in Hepatic Hydrothorax: A 10-Year Experience

Abstract: Thoracoscopic mesh repair for refractory HH improves symptoms and lowers the recurrence rate.

Cited by 36 publications

References 32 publications

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence‐Based Review and Guidance

Hepatic hydrothorax: An update and review of the literature

Contact Info

Product

Resources

About